Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutic...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

RaiderNation5413 Jun. 22 at 3:17 PM

$AEON I'm jumping ship. Far too long believing in this company. I survived their last reverse split only to re-accumulate another losing hand. Thousands in losses and a current average this stock will perhaps never see... It's time. Good luck to all, hope this pans out for future investors.

0 · Reply

Traidn Jun. 20 at 11:58 PM

$AEON I AM A GAMBLER AT 5 CENTS.

0 · Reply

TWITLIEDETECTOR Jun. 17 at 6:23 PM

$AEON they ran out of money to pump

0 · Reply

ClassiTrader Jun. 17 at 6:43 AM

$AEON holders meeting 👀 today 1 pm

0 · Reply

BryceyBoy Jun. 15 at 5:43 PM

$AEON all you folks still holding out for hope? Or has anyone else pulled out?

1 · Reply

flywithfitz81 Jun. 14 at 9:01 AM

$AEON $PSTV as the reat if Pharma: it is near impossible to get drugs through the current FDA. A few other bio stocks I follow have the same issue. Slow-rolling and then the requirement to negotiate for more and more working capital. Then these companies are making deals to insiders friends, basically paying out shares as protection to defend against coordinated short attacks. The shorts understand that R. Kennedy has no intention of helping, he is profiting off this. The industry is garbage right now.

1 · Reply

RaiderNation5413 Jun. 10 at 6:17 PM

$AEON No price bounce after Headache Society presentation in Orlando. Stagnant.

0 · Reply

TWITLIEDETECTOR Jun. 9 at 6:36 PM

$AEON these guys suck!

0 · Reply

Eight88 Jun. 2 at 5:56 PM

$AEON My theory on why this hasn’t moved yet and this is ALL SPECULATION, is that the PDT rule gets lifted in a few days. There haven’t really been many hard pumps yet and I think part of that could be because everyone is waiting for this rule to officially go away.

1 · Reply

RaiderNation5413 Jun. 1 at 6:09 PM

$AEON I'm thinking August is coming..fast. Can I assume that if they can't get back to 1.00usd, and maintain it, they may request another reverse split? Seems even now it would be a rushed vote to clear way for such action. I went through the last reverse with these guys...it's ugly, especially when their price continues to fall or lay stagnant post split.

0 · Reply

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

May 14, 2026, 4:05 PM EDT - 6 weeks ago

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:00 PM EDT - 6 weeks ago

AEON Biopharma Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 6 weeks ago

AEON Biopharma Quarterly report: Q1 2026

2026-05-14T14:19:48.000Z - 6 weeks ago

Aeon Biopharma management to meet virtually with Lake Street

May 14, 2026, 7:00 AM EDT - 6 weeks ago

AEON Biopharma Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Proxy statement: Proxy filing

Apr 24, 2026, 4:05 PM EDT - 2 months ago

AEON Biopharma Sets Annual Shareholder Meeting

2026-04-06T01:20:06.000Z - 2 months ago

Aeon receives additional notice related to NYSE American listing standards

Apr 3, 2026, 4:10 PM EDT - 2 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Apr 3, 2026, 4:05 PM EDT - 2 months ago

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

Mar 30, 2026, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Mar 30, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Earnings release: Q4 2025

2026-03-25T12:17:47.000Z - 3 months ago

Aeon Biopharma announces FDA feedback after Type 2a meeting

2026-03-09T20:45:55.000Z - 3 months ago

Aeon Biopharma appoints John Bencich as CFO

ACHV

2026-02-09T21:45:15.000Z - 4 months ago

Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders

Feb 9, 2026, 7:00 AM EST - 4 months ago

AEON Biopharma Registration statement: Registration Filing

Jan 22, 2026, 7:00 AM EST - 5 months ago

AEON Biopharma Slides: Corporate presentation

2026-01-21T21:25:21.000Z - 5 months ago

Aeon Biopharma reports BPD Type 2a meeting with FDA

Jan 21, 2026, 4:05 PM EST - 5 months ago

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Dec 29, 2025, 7:00 AM EST - 6 months ago

AEON Biopharma Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 6 months ago

AEON Biopharma Proxy statement: Proxy Filing

Dec 15, 2025, 4:05 PM EST - 6 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

2025-11-20T13:46:22.000Z - 7 months ago

Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA

Nov 20, 2025, 8:30 AM EST - 7 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

2025-11-14T13:35:33.000Z - 7 months ago

Aeon Biopharma reports Q3 EPS (39c) vs ($11.24) last year

Nov 14, 2025, 8:30 AM EST - 7 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 14, 2025, 8:30 AM EST - 7 months ago

AEON Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 7 months ago

AEON Biopharma Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

AEON Biopharma Proxy statement: Proxy Filing

Nov 13, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Nov 13, 2025, 7:00 AM EST - 8 months ago

AEON Biopharma Proxy statement: Proxy Filing

2025-10-01T12:20:41.000Z - 9 months ago

Aeon Biopharma announces FDA BPD Type 2a meeting for ABP-450

Oct 1, 2025, 8:00 AM EDT - 9 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:00 PM EDT - 11 months ago

AEON Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

AEON Biopharma Earnings release: Q2 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

May 19, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Quarterly report: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 25, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

2025-04-21T20:16:30.000Z - 1 year ago

Aeon Biopharma appoints Rob Bancroft as CEO

Apr 21, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 23, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

2025-01-06T14:15:17.000Z - 1 year ago

Aeon Biopharma prices 40M units at 50c in underwritten public offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Earnings release: Q3 2024

2024-09-30T12:11:48.000Z - 1 year ago

Aeon Biopharma announces outcome from FDA biosimilar advisory meeting

Aug 19, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

2024-08-15T10:13:15.000Z - 2 years ago

Aeon Biopharma files $200M mixed securities shelf

2024-08-14T10:11:02.000Z - 2 years ago

Aeon Biopharma price target lowered to $5 from $6 at H.C. Wainwright

Aug 12, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q2 2024

Jul 23, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

May 31, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

2024-05-29T12:12:33.000Z - 2 years ago

Aeon Biopharma discontinues Phase 2 study of ABP-450 in chronic migraine

May 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 24, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Earnings release: Q3 2023

Oct 23, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 18, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Registration statement: Registration Filing

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 3 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

RaiderNation5413 Jun. 22 at 3:17 PM

0 · Reply

Traidn Jun. 20 at 11:58 PM

$AEON I AM A GAMBLER AT 5 CENTS.

0 · Reply

TWITLIEDETECTOR Jun. 17 at 6:23 PM

$AEON they ran out of money to pump

0 · Reply

ClassiTrader Jun. 17 at 6:43 AM

$AEON holders meeting 👀 today 1 pm

0 · Reply

BryceyBoy Jun. 15 at 5:43 PM

$AEON all you folks still holding out for hope? Or has anyone else pulled out?

1 · Reply

flywithfitz81 Jun. 14 at 9:01 AM

1 · Reply

RaiderNation5413 Jun. 10 at 6:17 PM

$AEON No price bounce after Headache Society presentation in Orlando. Stagnant.

0 · Reply

TWITLIEDETECTOR Jun. 9 at 6:36 PM

$AEON these guys suck!

0 · Reply

Eight88 Jun. 2 at 5:56 PM

1 · Reply

RaiderNation5413 Jun. 1 at 6:09 PM

0 · Reply

TWITLIEDETECTOR May. 30 at 7:12 PM

$AEON read the filings. they have no clue when they will be ready.

0 · Reply

TWITLIEDETECTOR May. 30 at 2:58 AM

$AEON they have to pump it soon. back to $1.09 in a few weeks. always said the pumping was bullshit. not owning. just reading filings

0 · Reply

Eight88 May. 29 at 6:07 PM

$AEON these cunts going to get de-listed.

0 · Reply

ka1954 May. 27 at 9:50 PM

$AEON this stock is fucked up. last 2-3 weeks, i am seeing a lot of small stocks going 200%+.

0 · Reply

Allf2 May. 27 at 8:45 AM

$AEON For Daewoong, the long-term commercial reward of seizing the global BOTOX® therapeutic market via a streamlined biosimilar pathway vastly outweighs the short-term pain of absorbing AEON's losses and triggering equity dilution. Expect structural capital maneuvers prior to the August 2026 NYSE compliance deadline to keep the FDA timeline breathing. The shareholders' suffering will be considerable.

1 · Reply

TWITLIEDETECTOR May. 24 at 3:58 AM

$AEON this company and stock is a POS

2 · Reply

SuperGreenToday May. 22 at 2:53 AM

$AEON

0 · Reply

Traidn May. 21 at 7:36 PM

$AEON Reverse split soon?

0 · Reply

Traidn May. 21 at 7:30 PM

$AEON This.

0 · Reply

BryceyBoy May. 18 at 1:42 PM

$AEON Well fellas....I wanted to continue to hold out for as long as possible but I just dont see this getting any better at this point so I sold. I will continue to check periodically but I am worried for another RS like before and I dont want to have to build back up from there. I genuinely though this was going to be our stock that hit big but it just isnt getting there and the fact that management is so silent on everything is just slightly annoying. Good luck to you all.

1 · Reply

TWITLIEDETECTOR May. 16 at 5:34 AM

$AEON pathetic. i read the filings. resistance has built up. no good

0 · Reply

Pidxr May. 15 at 9:24 PM

$HCWB was hoping $AEON would behave this way this year too.

0 · Reply

Market Cap	16.68M
Revenue (ttm)	0.00
Net Income (ttm)	-39.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,025
Avg Vol	83,646
Day's Range	N/A - N/A
Shares Out	25.30M
Stochastic %K	90%
Beta	0.61
Analysts	Strong Sell
Price Target	$6.70